Men's Health News

RSS

Researchers conduct real-time metabolic imaging in human patient with prostate tumor

A UCSF research collaboration with GE Healthcare has produced the first results in humans of a new technology that promises to rapidly assess the presence and aggressiveness of prostate tumors in real time, by imaging the tumor's metabolism.

30 Nov 2010

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has commenced, with the initiation of patient dosing in a Phase 1-2 clinical study.

30 Nov 2010

FDA approves Axiron topical solution CIII for testosterone replacement therapy in men

Acrux , a drug delivery company that develops and commercializes patented pharmaceutical products for global markets, and Eli Lilly Company today announced that the United States Food and Drug Administration (FDA) has approved the Axiron® topical solution CIII for testosterone replacement therapy in men. Axiron is the first testosterone topical solution approved for application via an underarm applicator.

29 Nov 2010

Study finds association between DGKK gene and hypospadias

Hypospadias is a common congenital malformation of the male external genitalia, affecting 1 in 375 boys. In hypospadias patients, the urethral opening is not located at the tip of the penis, but somewhere halfway, at the base of the penis, or even in the scrotum.

29 Nov 2010

ESF report: Reduced male fertility may contribute to low birth rates

Reduced male fertility may be making it even harder for couples to conceive and be contributing to low birth rates in many countries, reveals a new European Science Foundation (ESF) report launching today at the IPSEN meeting in Paris.

28 Nov 2010

Segasist Technologies receives HTX funding for clinical validation of prostate MRI software

Segasist Technologies, a Canadian software company developing contouring productivity tools for medical imaging, has today announced the receipt of funding from The Health Technology Exchange (HTX) towards support of clinical validation of its software, to be conducted at the Lawson Health Research Institute and London Health Sciences Centre (London, Ontario). Experts from Sunnybrook Research Institute and Sunnybrook Health Sciences Centre will also participate in the validation process by providing input in the form of gold standard contours.

26 Nov 2010

HIV treatment drugs also help prevent HIV infection in high-risk men: Study

In a significant advance for HIV prevention research, a clinical trial confirms that the same drugs used for treating HIV can also help prevent HIV infection in the first place.

24 Nov 2010

Daily oral antiretroviral reduces HIV infection risk in MSM by 44%, study finds

A study that included nearly 2,500 HIV-negative men and transgender women who have sex with men has shown that a daily dose of Truvada, a pill containing the AIDS drugs emtricitabine and tenofovir, "can reduce risk of contracting [HIV] by an average of 44% - and by more than 70% if the subjects" follow the regimen closely, Los Angeles Times reports (Maugh, 11/23).

24 Nov 2010

Men failing to protect eyes from injuries: Experts

A review looking at patients attending a Melbourne hospital’s emergency department with a serious eye injury shows that most of them could be prevented by proper eye protection. Men’s particular lack of eye protection while using power tools and lawn mowers, usually during routine house maintenance, were the other major factors in the injury cases say the researchers.

23 Nov 2010

Study finds no link between prostate cancer clinical stage and risk of recurrence after radical prostatectomy

A new study challenges the current staging system that determines the extent or severity of prostate cancer that has not metastasized. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study found that there is no link between localized prostate cancer's clinical stage and a patient's risk of cancer recurrence after having his prostate removed.

22 Nov 2010

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Department of Defense (DoD) has recommended STA-9584, a novel vascular disrupting agent (VDA) currently in pre-clinical development at Synta, be funded for study in advanced prostate cancer.

19 Nov 2010

Expert panel to endorse newly approved therapeutic vaccine for advanced prostate cancer

Provenge is one step closer to being covered by Medicare. An expert panel voted Wednesday to endorse the newly approved therapeutic vaccine for men with advanced prostate cancer.

19 Nov 2010

Multidisciplinary clinic approach can improve survival in patients with aggressive prostate cancer

A research team from the National Cancer Institute (NCI) designated Kimmel Cancer Center (KCC) at Jefferson has concluded for the first time that a multidisciplinary clinic approach to aggressive prostate cancer can improve survival in patients. The results from the 15-year study of the multidisciplinary clinic can be found in the November issue of Journal of Oncology Practice.

18 Nov 2010

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.

18 Nov 2010

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Medicare roundup: Payment cuts irk healthcare industry; officials mull new prostate-cancer treatment

Doctors across the United States are taking a wait-and-see approach while Congress decides whether or not to allow a scheduled 23% cut in Medicare reimbursement rates to take effect on Dec. 1.

17 Nov 2010

HUPTI's first group of patients complete prostate cancer treatment

The Hampton University Proton Therapy Institute's first group of patients completed their course of treatment for prostate cancer.

16 Nov 2010

Men treated with hormone-based therapy for prostate cancer face higher risk of colorectal cancer: Study

Men treated with hormone-based therapy for prostate cancer faced a 30 percent to 40 percent higher risk of colorectal cancer, compared to patients who did not receive this treatment, according to a new study.

16 Nov 2010

GTx presents preclinical studies of GTx-758 and GTx-230 for treatment of cancer

GTx, Inc. announced the presentation of preclinical studies evaluating GTx-758, a selective estrogen receptor alpha agonist being developed for first line treatment of advanced prostate cancer, and GTx-230, a novel microtubule polymerization inhibitor.

15 Nov 2010

Light alcohol consumption benefits post-coronary bypass patients

Light to moderate alcohol consumption (about two to three drinks daily) among male coronary artery bypass patients was associated with 25 percent fewer subsequent cardiovascular procedures, heart attacks, strokes and death compared to non-drinkers, in a study presented at the American Heart's Association's Scientific Sessions 2010.

15 Nov 2010

Men's Health News

Researchers conduct real-time metabolic imaging in human patient with prostate tumor

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

FDA approves Axiron topical solution CIII for testosterone replacement therapy in men

Study finds association between DGKK gene and hypospadias

ESF report: Reduced male fertility may contribute to low birth rates

Segasist Technologies receives HTX funding for clinical validation of prostate MRI software

HIV treatment drugs also help prevent HIV infection in high-risk men: Study

Daily oral antiretroviral reduces HIV infection risk in MSM by 44%, study finds

Men failing to protect eyes from injuries: Experts

Study finds no link between prostate cancer clinical stage and risk of recurrence after radical prostatectomy

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Expert panel to endorse newly approved therapeutic vaccine for advanced prostate cancer

Multidisciplinary clinic approach can improve survival in patients with aggressive prostate cancer

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Medicare roundup: Payment cuts irk healthcare industry; officials mull new prostate-cancer treatment

HUPTI's first group of patients complete prostate cancer treatment

Men treated with hormone-based therapy for prostate cancer face higher risk of colorectal cancer: Study

GTx presents preclinical studies of GTx-758 and GTx-230 for treatment of cancer

Light alcohol consumption benefits post-coronary bypass patients

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Latest News